Tyra Biosciences announced the appointment of Habib Dable to its Board of Directors, adding a seasoned biopharmaceutical executive with more than 30 years of leadership experience.
Dable brings extensive expertise in scaling global biopharmaceutical businesses and leading commercial strategy across multiple therapeutic areas. He most recently served as president and chief executive officer of Acceleron Pharma, where he led the company through significant growth culminating in its acquisition by Merck in 2021. Prior to that, he spent more than two decades at Bayer AG, including roles as president of U.S. Pharmaceuticals and global head of specialty medicine.
Tyra said the appointment comes as the company advances its pipeline of precision medicines targeting fibroblast growth factor receptor biology, including its lead candidate dabogratinib, which is being developed across multiple oncology and genetic indications.
Dable currently serves on the boards of several biotechnology companies and is an advisor at RA Capital Management. His experience is expected to support Tyra’s strategic and commercial development as it progresses toward later-stage clinical and potential commercialization milestones.
The company also announced that Gilla Kaplan will conclude her service on the board at the upcoming annual meeting.
KEY QUOTES
“As TYRA advances into its next phase of growth, Habib brings the kind of experience and strategic insight that will be critical at the Board level. His proven track record in global product launches and strategic execution will be invaluable as we look to develop and commercialize dabogratinib for LG-UTUC, IR NMIBC and ACH. His experience building leading franchises in specialty medicine aligns with our ambition to unlock the full potential of FGFR3 inhibition and deliver meaningful therapies to patients.”
Todd Harris, Chief Executive Officer, Tyra Biosciences
“The opportunity at TYRA is grounded in structure-based drug design and clinical translational expertise. FGFR3 represents one of the most compelling and difficult-to-drug targets in oncology and genetic conditions, and dabogratinib is uniquely differentiated and positioned to realize meaningful potential. With its 3×3 strategy, TYRA is building a broad, multi-indication franchise that has the potential to drive substantial long-term commercial impact. I look forward to contributing as a Board member as TYRA advances its pipeline.”
Habib Dable, Board Member, Tyra Biosciences
